Media headlines about Aptevo Therapeutics (NASDAQ:APVO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.9737164548051 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Aptevo Therapeutics (NASDAQ APVO) remained flat at $1.67 on Friday. 28,695 shares of the company’s stock were exchanged. Aptevo Therapeutics has a 1-year low of $1.60 and a 1-year high of $3.61. The stock has a 50 day moving average of $1.81 and a 200-day moving average of $1.96. The stock’s market capitalization is $35.77 million.
Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.08. Aptevo Therapeutics had a negative return on equity of 64.80% and a negative net margin of 296.64%. The firm had revenue of $10.76 million for the quarter. On average, analysts predict that Aptevo Therapeutics will post ($2.26) EPS for the current year.
Separately, ValuEngine cut Aptevo Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
Receive News & Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
